Tumor biomarkers detection in blood samples

doi:10.3877/cma.j.issn.2095-5820.2014.01.003

Abstract

Abstract:

With the development of personalized medicine in cancer, targeted therapy based on precise detection of tumor biomarkers becomes more and more important. Tumor biomarkers detection in blood shows advantages in sample collection and flexibility of detecting methods, compared to tests using tumor biomarkers. And detection in blood samples could be applied in clinical practice better with the development of screening techniques and strategies.

Key words: Tumor marker, Personalized medicine, Blood sample

Yinchen Shen, Xiaohong Han. Tumor biomarkers detection in blood samples[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2014, 02(01): 11-15.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2014.01.003

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2014/V02/I01/11

References 49

1	陈万青, 郑荣寿, 曾红梅, 等. 中国恶性肿瘤发病趋势分析和预测[J].中华预防医学杂志, 2012, 46(7): 581-586.
2	Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
3	Mehan MR, Ayers D, Thirstrup D, et al. Protein signature of lung cancer tissues[J]. PLoS One, 2012, 7(4), e35157.
4	Luo G, Xiao Z, Long J, et al. CA125 is Superior to CA19-9 in predicting the resectability of pancreatic cancer[J]. J Gastrointest Surg,2013. [Epub ahead of print].
5	Hou SC, Xiao MB, Ni RZ, et al. Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinoma[J].Oncol Lett, 2013, 6(4): 1152-1158.
6	Bendall SC, Simonds EF, Qiu P, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum[J]. Science, 2011, 332(6030): 687-696.
7	Dittmar T, Heyder C, Gloria-Maercker E, et al. Adhesion molecules and chemok-ines: the navigation system for circulating tumor(stem) cells to metastasize in an organ-specific manner[J]. Clin Exp Metastasis, 2008, 25(1): 11-32.
8	Terstappen LW, Rao C, Gross S, et al. Peripheral blood tumor cell load reflects the clinical activity of the disease in patients with carcinoma of the breast[J]. Int J Oncol, 2000, 17(3): 573-578.
9	Naito T, Tanaka F, Ono A, et al. Prognostic impact of circulating tumor cells in patients with small cell lung cancer[J]. J Thorac Oncol, 2012,7(3): 512-519.
10	Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer:association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib[J]. Clin Cancer Res, 2012, 18(8): 2391-2401.
11	Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight[J]?Nat Rev Genet, 2008, 9(2): 102-114.
12	Di Leva G, Croce CM. Roles of small RNAs in tumor formation[J].Trends Mol Med, 2010, 16(6): 257-267.
13	Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2[J]. Proc Natl Acad Sci U S A, 2005,102(39): 13944-13949.
14	Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers[J].BMC Cancer, 2011, 11: 374.
15	Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(10): 1721-1726.
16	Lippitz BE. Cytokine patterns in patients with cancer: a systematic review[J]. Lancet Oncol, 2013, 14(6): e218-228.
17	Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy[J]. J Immunother, 1997, 20(3): 165-177.
18	McKarns SC, Schwartz RH, Kaminski NE. Smad3 is essential for TGF-beta 1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation[J]. J Immunol, 2004,172(7): 4275-4284.
19	Lebman DA, Edmiston JS. The role of TGF-beta in growth, diff erentiation, and, maturation of B lymphocytes[J]. Microbes Infect,1999, 1(15): 1297-1304.
20	Teicher BA. Transforming growth factor-beta and the immune response to malignant disease[J]. Clin Cancer Res, 2007, 13(21): 6247-6251.
21	Lin Y, Kikuchi S, Obata Y, et al. Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer[J]. J Gastroenterol Hepatol, 2006, 21(2): 432-437.
22	Saito H, Tsujitani S, Oka S, et al. An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma[J]. Anticancer Res, 2000, 20(6B): 4489-4493.
23	Ivanovic V, Demajo M, Krtolica K, et al. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients[J]. Clin Chim Acta, 2006, 371(1-2): 191-193.
24	Nikiteas NI, Tzanakis N, Gazouli M, et al. Serum IL-6, TNF-alpha and CRP levels in Greek colorectal cancer patients: prognostic implications[J]. World J Gastroenterol, 2005, 11(11): 1639-1643.
25	Chen CJ, Sung WW, Su TC, et al. High expression of interleukin 10 might predict poor prognosis in early stage oral squamous cell carcinoma patients[J]. Clin Chim Acta, 2012, 415: 25-30.
26	Nacinovic-Duletic A, Stifter S, Dvornik S, et al. Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma[J]. Int J Lab Hematol, 2008, 30(3): 230-239.
27	Shibata M, Nezu T, Kanou H, et al. Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer[J]. J Clin Gastroenterol,2002, 34(4): 416-420.
28	Ciszak L, Kosmaczewska A, Werynska B, et al. Impaired zeta chain expression and IFN-gamma production in peripheral blood T and NK cells of patients with advanced lung cancer[J]. Oncol Rep, 2009, 21(1): 173-184.
29	Okamoto M, Azuma K, Hoshino T, et al. Correlation of decreased survival and IL-18 in bone metastasis[J]. Intern Med, 2009, 48(10): 763-773.
30	Lonning S, Mannick J, McPherson JM. Antibody targeting of TGF-β in cancer patients[J]. Curr Pharm Biotechnol, 2011, 12(12): 2176-2189.
31	Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial[J]. Lancet, 2008, 372(9652): 1809-1818.
32	Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, doubleblind phase 3 non-inferiority trial[J]. Lancet Oncol, 2013, 14(10): 953-961.
33	Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer[J]. J clin Oncol, 2009, 27(16): 2653-2659
34	Taly V, Pekin D, Benhaim L, et al. Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients[J]. Clin Chem, 2013. [Epub ahead of print].
35	Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer[J]. J Clin Oncol, 2010, 28(23): 4985-4995.
36	Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I and prostate cancer risk: A prospectivstudy[J]. Science,1998, 279(5350): 563-566.
37	Chan JM, Stampfer MJ, Ma J, et al. Insulinlike growth factor-I (IGF-I)and IGF binding protein-3 as predictors of advanced-stage prostate cancer[J]. J Natl Cancer Inst, 2002, 94(14): 1099-1106.
38	Hankinson SE, Willett WC, Colditz GA, et al: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer[J]. Lancet, 1998, 351(9113): 1393-1396.
39	Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3[J]. J Natl Cancer Inst, 1999, 91(7): 620-625.
40	Bender LM, Nahta R. Her2 cross talk and therapeutic resistance in breast cancer[J]. Front Biosci, 2008, 13: 3906-3912.
41	Chakraborty AK, Liang K, DiGiovanna MP. Co-targeting insulinlike growth factor I receptor and HER2: Dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer[J]. Cancer Res, 2008,68(5): 1538-1545.
42	Lu D, Zhang H, Koo H, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity[J]. J Biol Chem, 2005, 280(20): 19665-19672.
43	Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)[J]. J Natl Cancer Inst, 2001, 93(24): 1852-1857.
44	Ueda S, Hatsuse K, Tsuda H, et al. Potential crosstalk between insulinlike growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer[J]. Mod Pathol,2006, 19(6): 788-796.
45	Assy N, Pruzansky Y, Gaitini D, et al. Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction[J]. J Hepatol, 2008, 49(1): 34-42.
46	Wu YL, Ye J, Zhang S, et al. Clinical significance of serum IGF-I,IGF-II and IGFBP-3 in liver cirrhosis[J]. World J Gastroenterol, 2004,10(18): 2740-2743.
47	Cho EJ, Lee JH, Yoo JJ, et al. Serum insulin-like growth factor-I level Is an independent predictor of recurrence and survival in early hepatocellular carcinoma: A prospective cohort study[J]. Clin Cancer Res, 2013, 19(15): 4218-4227.
48	Kamiya K, Watanabe M. KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer[J]. Respirology, 2011, 16(6): 976-982.
49	Niimi R, Matsumine A, Iino T, et al. Soluble neural-cadherin as a novel biomarker for malignant bone and soft tissue tumors[J]. BMC Cancer, 2013, 13(1): 309.

[1]	Tiantian He, Wencong Yao, Shanling Liu, He Wang, Xuemei Zhang. Effects of storage time of whole blood samples on enzyme activity assay for diagnosis of mucopolysaccharidosis at low temperature [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2021, 17(05): 566-573.
[2]	Haitao Chen, Jingyao Zhang, Bing Zhu, Jiajia Guan, Jun Fu. Diagnostic and prognostic value of serum cell-free DNA in gastric cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(01): 18-22.
[3]	Jia Yan, Shuangchi Liu, Zhengyu Wang. Progress in the research and application of tumor markers for gallbladder cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 391-394.
[4]	Xiaoman Chen, Haibo Zhang, Manjie Xue, Bo Wei, Jun Shao, Xiaoyan Han. Impact of -80℃ cryopreservation on miRNA markers in colorectal cancer plasma sample [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(01): 24-27.
[5]	Sizhe Xu, Gongjian He, Li Zeng, Huijia Yang, Fang Wang. The predictive value of ultrasonography combined with tumor markers for occult lymph node metastasis in central area of cN0 stage micropapillary thyroid carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2021, 15(03): 314-318.
[6]	Wenxin Xie, Le Ma, Ye Liu, Xiaoming Cao, Wanchun Zhang. The application value of prostate specific membrane antigen PET/CT in the diagnosis and treatment of renal cell carcinoma [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 514-519.
[7]	Xinxiong Li, Zaizhong Zhang, Hu Zhao, Chunhong Xiao, Lie Wang. Progress of exosome contents as diagnostic markers for pancreatic cancer [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(01): 53-57.
[8]	Xiaopeng Chen, Jiani Wang, Qinghai Lian, Jiumei Yang. Expression of VOPP1 in hepatocellular carcinoma and its relationship with prognosis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 876-882.
[9]	Chengming Ding, Jiafeng Hou, Guangwei Tao. Early diagnosis and screening of hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(01): 22-28.
[10]	Hongxia Yan, Xiaojuan Wang, Yixun Zhang. The effect of type 2 diabetes on tumor markers， clinicopathology and prognosis in patients with colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 483-487.
[11]	Chunlin Wang, Yuliuming Wang, Hao Zhang, Yunxiao Liu, Meng Wang, Guiyu Wang. Clinical predictive model for predicting distant metastasis of colorectal cancer: combined with preoperative CEA, CA19-9 and clinicopathological factors [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2022, 11(03): 205-211.
[12]	Fei Wan, Yongjun Ren. Research progress on tumor markers in primary hepatocellular carcinoma [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(01): 77-81.
[13]	Chenfan Li, Lihua Wu, Zeyu Zheng, Yueping Zheng, Yun Xie, Jie Liu, Bifang Wu, Ruizhang Su, Man Wan, Zhaoxu Tian, Yiqun Hu. Progress of diagnostic methods of pancreatic cancer by endoscopic ultrasound-guided fine-needle aspiration [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2022, 12(02): 102-107.
[14]	Jing Mo, Guowei Chen, Shiyu Zhang. Effect of intraperitoneal hyperthermic perfusion chemotherapy at different times after operation on tumor marker levels in patients with ovarian cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(02): 165-170.
[15]	Qiang Wang, Huan Zhang, Jun Pan. Significance of tumor markers in the differential diagnosis of pleural effusion in elderly patients [J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2022, 09(04): 16-21.

Please choose a citation manager

Content to export